| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g | |||
| Other Sizes |
Purity: ≥98%
Terbutaline Sulfate (Terbutaline hemisulfate; Bronclyn, Brethine, KWD-2019; KWD2019; Bricanyl, Brethaire, Terbulin) is a potent and selective β2-adrenergic receptor agonist used for the treatment of allergic asthma. IIt has an IC50 of 53 NM for β2-adrenergic receptor activation, while it has negligible or no effect on alpha-adrenergic receptors. The medication preferentially affects β2-adrenergic receptors, but it stimulates beta-adrenergic receptors less selectively than beta2-agonists, which are more selectively stimulating. The clinical efficacy of terbutaline in the treatment of allergic asthma is attributed to its inhibition of antigen-induced histamine release from human lung tissue that has been passively sensitized.
| Targets |
β adrenergic receptor ( IC50 = 53 nM )
|
|---|---|
| ln Vitro |
In vitro activity: Terbutaline is an alpha-adrenergic receptor-selective β2-adrenergic bronchodilator with negligible or no effect on both. Beta-adrenergic receptors are stimulated less selectively by the drug than by relatively selective beta2-agonists, but it has a preferential effect on β2-adrenergic receptors. When used to treat allergic asthma, terbutaline is clinically effective because it blocks the release of histamine from human lung tissue that has been passively sensitized to an antigen.[1] Additionally, for all BChE variants, terbutaline exhibits competitive reversible inhibition. UU, FF, and AA homozygotes have dissociation constants of 0.18, 0.31, and 3.3 mM, in that order.[2]
- In a biomimetic cell membrane model, terbutaline sulphate showed interaction with lipid bilayers, altering membrane fluidity and potentially enhancing its binding to β₂-AR [2] - In RAW264.7 macrophages, terbutaline (10 μM) increased MKP-1 expression and reduced LPS-induced TNF-α production, indicating anti-inflammatory effects mediated by MKP-1 activation [3] |
| ln Vivo |
Terbutaline seems to stimulate beta-receptors in the uterine smooth muscles, bronchi, and vessels more strongly (β2 receptors) than it does the beta-receptors in the heart (β1 receptors). This medication may have some cardiostimulatory effects and stimulate the central nervous system in addition to relaxing smooth muscle and inhibiting uterine contractions.[3]
- In a randomized controlled trial (RCT) involving 60 pregnant women, terbutaline (0.25 mg subcutaneous injection every 20 minutes for 3 doses) was compared with nifedipine for tocolysis. Terbutaline showed comparable efficacy in delaying delivery but caused more maternal tachycardia and tremors [1] - In ob/ob mice with diabetic polyneuropathy, terbutaline (1 mg/kg, intraperitoneal injection) reduced mechanical allodynia through activation of β₂-AR and δ opioid receptors, as demonstrated by reversal of effects with selective antagonists [4] |
| Cell Assay |
Cell Line: J774 macrophages
Concentration: 0-10 μM Incubation Time: 1 hour Result: Enhanced MKP-1 expression in J774 macrophages in a dose-dependent manner. - β₂-AR binding assay: HEK293 cells transfected with β₂-AR were incubated with radiolabeled terbutaline. Specific binding was measured by filtration, and competition experiments with unlabeled agonists determined receptor affinity [2] - Inflammatory cytokine assay: RAW264.7 cells treated with terbutaline (1-10 μM) were stimulated with LPS. TNF-α levels in culture supernatants were quantified by ELISA, showing dose-dependent reduction [3] |
| Animal Protocol |
Adult male ob/ob mice
0.5 mg/kg Intraperitoneal injection; 0.5 mg/kg; twice a day; 20 days - Tocolysis model: Pregnant women (gestational age 28-34 weeks) received terbutaline (0.25 mg subcutaneous) or nifedipine (10 mg orally) every 20 minutes for 3 doses. Maternal heart rate, blood pressure, and uterine activity were monitored [1] - Diabetic neuropathy model: ob/ob mice (8 weeks old) were treated with terbutaline (1 mg/kg, intraperitoneal) daily for 7 days. Mechanical allodynia was assessed using von Frey filaments, and spinal cord tissues were analyzed for β₂-AR and δ opioid receptor expression [4] |
| ADME/Pharmacokinetics |
ADME/Pharmacokinetics: - Oral bioavailability: 15±6% - Plasma protein binding: 25% - Half-life: 3-4 hours
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Medication Use During Lactation Maternal oral or inhaled terbutaline is unlikely to affect breastfed infants. Authors of multiple reviews and expert guidelines agree that its use during breastfeeding is acceptable due to the low bioavailability of inhaled bronchodilators and low maternal serum concentrations after administration. Terbutaline, as a tocolytic, may shorten the duration of breastfeeding. ◉ Effects on Breastfed Infants Two papers reported on four infants aged 3 to 8 weeks who were breastfed while their mothers administered 2.5 or 5 mg of terbutaline orally three times daily. None of the infants showed signs of sympathetic excitation and all developed normally. These cases are also summarized in a third publication. ◉ Effects on Lactation and Breast Milk A small retrospective study in Serbia found that mothers who received beta-agonists (fenoterol or phenobarbital) with similar pharmacological effects to terbutaline as tocolytics had shorter breastfeeding durations than mothers who did not receive tocolytics (4.5 months vs. 9.5 months). It is currently unclear whether terbutaline has a similar effect. A study at an Australian hospital compared breastfeeding outcomes in women who underwent cesarean sections in two phases. In the first phase, women undergoing grade I or II cesarean sections did not receive terbutaline treatment preoperatively (n = 423). In the second phase, all women undergoing grade I or II cesarean sections received a subcutaneous injection of 250 micrograms of terbutaline as a tocolytic, unless there were contraindications at the time of the decision to perform the cesarean section (n = 253). Breastfeeding rates at discharge were 95% in the first phase and 99% in the second phase, a statistically significant difference. - Common adverse reactions: tremor, tachycardia, headache, and hypokalemia - Overdose symptoms: nausea, vomiting, ventricular arrhythmias, and metabolic acidosis - Plasma protein binding rate: 25% |
| References |
|
| Additional Infomation |
Terbutaline is a selective β₂-adrenergic receptor agonist used to relieve bronchospasm and inhibit uterine contractions. Activation of its β₂-adrenergic receptors leads to cAMP-mediated smooth muscle relaxation and anti-inflammatory effects. Warnings from the U.S. Food and Drug Administration (FDA) include cardiovascular risks (e.g., arrhythmias) and potential complications of preterm birth [4]. Terbutaline sulfate is an ethanolamine sulfate that functions in relation to terbutaline. Terbutaline sulfate is the sulfate form of terbutaline, an ethanolamine derivative with bronchodilation and uterine contraction inhibition effects. Terbutaline sulfate selectively binds to and activates β₂-adrenergic receptors, activating intracellular adenylate cyclase via trimeric G protein, which subsequently increases the production of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels can mediate bronchial and vascular smooth muscle relaxation by activating protein kinase A (PKA), which phosphorylates proteins that control muscle tone. cAMP also inhibits intracellular calcium ion release, reduces calcium ion entry into cells, and induces intracellular calcium ion chelation, all of which contribute to airway muscle relaxation. Terbutaline sulfate also increases mucociliary clearance and reduces the release of inflammatory cytokines. A selective β2-adrenergic agonist used as a bronchodilator and uterine contraction inhibitor. See also: Terbutaline (with active ingredient).
|
| Molecular Formula |
C12H20NO5S0.5
|
|
|---|---|---|
| Molecular Weight |
548.65
|
|
| Exact Mass |
548.24
|
|
| Elemental Analysis |
C, 52.54; H, 7.35; N, 5.11; O, 29.16; S, 5.84
|
|
| CAS # |
23031-32-5
|
|
| Related CAS # |
Terbutaline; 23031-25-6
|
|
| PubChem CID |
441334
|
|
| Appearance |
White to off-white crystalline powder
|
|
| Density |
1.1840 (rough estimate)
|
|
| Boiling Point |
419.2ºC at 760 mmHg
|
|
| Melting Point |
246-248ºC
|
|
| Flash Point |
165.3ºC
|
|
| Vapour Pressure |
8.92E-08mmHg at 25°C
|
|
| Index of Refraction |
1.6900 (estimate)
|
|
| LogP |
4.248
|
|
| Hydrogen Bond Donor Count |
10
|
|
| Hydrogen Bond Acceptor Count |
12
|
|
| Rotatable Bond Count |
8
|
|
| Heavy Atom Count |
37
|
|
| Complexity |
286
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
S(=O)(=O)(O[H])O[H].O([H])C([H])(C1C([H])=C(C([H])=C(C=1[H])O[H])O[H])C([H])([H])N([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H].O([H])C([H])(C1C([H])=C(C([H])=C(C=1[H])O[H])O[H])C([H])([H])N([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
|
| InChi Key |
KFVSLSTULZVNPG-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/2C12H19NO3.H2O4S/c2*1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8;1-5(2,3)4/h2*4-6,11,13-16H,7H2,1-3H3;(H2,1,2,3,4)
|
|
| Chemical Name |
5-(2-(tert-butylamino)-1-hydroxyethyl)benzene-1,3-diol; sulfate (2:1)
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 120 mg/mL (437.45 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8227 mL | 9.1133 mL | 18.2266 mL | |
| 5 mM | 0.3645 mL | 1.8227 mL | 3.6453 mL | |
| 10 mM | 0.1823 mL | 0.9113 mL | 1.8227 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04973345 | Recruiting | Drug: Terbutaline | Asthma | Kanecia Obie Zimmerman | July 7, 2023 | Phase 2 Phase 3 |
| NCT05494307 | Not yet recruiting | Drug: Terbutaline Drug: Danazol |
Immune Thrombocytopenia | Peking University People's Hospital |
September 1, 2022 | Phase 2 |
| NCT00185887 | Completed | Drug: Terbutaline | Fetal Distress | Stanford University | October 2003 | Not Applicable |
| NCT05326269 | Completed | Drug: Terbutaline | Nonreassuring Fetal Status | Hospital Kemaman | April 23, 2017 | Not Applicable |
| NCT01096017 | Completed | Drug: Terbutaline Turbuhaler® Drug: Salbutamol pMDI Other: pMDI placebo pMDI |
Asthma | AstraZeneca | March 2010 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA